Media Coverage

FDA approves Spravato nasal spray for depression

FDA approves Spravato nasal spray for depression

Mar 6, 2019

BioSpace's Global Biopharma Roundup: February 21

BioSpace's Global Biopharma Roundup: February 21

Feb 21, 2019

J&J nears FDA approval for landmark depression drug to replace ketamine treatments

J&J nears FDA approval for landmark depression drug to replace ketamine treatments

Feb 13, 2019

Can We Treat Mood Disorders With Pharmacological Therapeutics?

Can We Treat Mood Disorders With Pharmacological Therapeutics?

Feb 1, 2019

Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

Jan 16, 2019

VistaGen CEO notes broad market potential of ketamine-like AV-101

VistaGen CEO notes broad market potential of ketamine-like AV-101

Nov 26, 2018

Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more

Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more

Oct 29, 2018

Company focus: VistaGen

Company focus: VistaGen

Oct 22, 2018

VistaGen acquires worldwide license of phase 3-ready CNS drug

VistaGen acquires worldwide license of phase 3-ready CNS drug

Oct 1, 2018

VistaGen nabs phase 3-ready social anxiety drug from Pherin

VistaGen nabs phase 3-ready social anxiety drug from Pherin

Sep 13, 2018